# Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

> **NCT01105117** · PHASE4 · COMPLETED · sponsor: **Actelion** · enrollment: 2 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** ACT-385781A (Actelion Epoprostenol)
- **DRUG:** Flolan®

## Key facts

- **NCT ID:** NCT01105117
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2012-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105117, "Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01105117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*